NOYADA 25mg/5ml price in UAE

Overview

Welcome to Dwaey, specifically on NOYADA 25mg/5ml Solution (Oral) page.
This medicine contains an important and useful components, as it consists of Captopril.
NOYADA 25mg/5ml is available in the market in concentration 5mg/ml and in the form of Solution (Oral).

MARTINDALE PHARMACEUTICALS is the producer of NOYADA 25mg/5ml and it is imported from UK, The most popular alternatives of NOYADA 25mg/5ml are listed downward .

Mode Of Action

Captopril competitively inhibits the conversion of angiotensin I (ATI) to angiotensin II (ATII), thus resulting in reduced ATII levels and aldosterone secretion. It also increases plasma renin activity and bradykinin levels. Reduction of ATII leads to decreased Na and water retention. This promotes vasodilation and BP reduction.

Indication

Hypertension
Congestive heart failure
Post Myocardial infarction
Diabetic nephropathy

Precaution

Patients on diuretics or with sodium depletion should discontinue diuretics or increase sodium intake prior to initiation of therapy. Renal impairment, SLE and other autoimmune collagen disorders and during concurrent use of immunosuppressant or leucopenic drugs, monitor WBC count and urinary protein before and during therapy. Lactation. Porphyria. Severe CHF. Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, drugs that act directly on the renin-angiotensin have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death Lactation: enters breast milk/not recommended (AAP states compatible with nursing)

Side Effects

>10% Hyperkalemia (1-11%) 1-10% Hypersensitivity rxns (4-7%)
Skin rash (4-7%)
Dysgeusia (2-4%)
Hypotension (1-2.5%)
Pruritus (2%)
Cough (0.5-2%)
Chest pain (1%)
Palpitations (1%)
Proteinuria (1%)
Tachycardia (1%) Frequency Not Defined Cardiac arrest
Orthostatic hypotension
Ataxia
Confusion
Depression
Somnolence
Angioedema
Photosensitivity
Neutropenia
ARF if renal artery stenosis
Renal impairment
Impotence Potentially Fatal: Neutropenia
usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.

Contra indication

Known hypersensitivity to the drug. Bilateral renal artery stenosis, hereditary angioedema; renal impairment; pregnancy.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy Category: C; D in 2nd & 3rd trimesters

Interaction

Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.